As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.

A study has suggested that the use of weight-loss jabs may be associated with wider health benefits, including a lower risk of stroke, dementia and heart attacks

A major new study has highlighted significant health risks associated with popular weight loss injections such as Ozempic, Wegovy, and Mounjaro. The research involved over two million patients and found that those using these medications have double the risk of developing pancreatitis – a potentially life-threatening inflammation of the pancreas.

Researchers said weight-loss drugs could affect health in eye-opening ways, but other experts say more work needs to be done to confirm this

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart disease, and obesity. Commonly marketed under brand names like Ozempic and Wegovy,

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks of addiction.